Business Wire

TX-ABB

9.10.2019 17:02:09 CEST | Business Wire | Press release

Share
ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future

ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas – showcasing a number of concept technologies, including a mobile YuMi® robot, which will be designed to assist medical and laboratory staff with laboratory and logistics tasks in hospitals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005527/en/

The dual-arm mobile YuMi® will be able to sense and navigate its way around its human co-workers autonomously, while learning to find different routes from one location to another. It has the potential to undertake a wide range of repetitive and time-consuming activities, including preparation of medicines, loading and unloading centrifuges, pipetting and handling liquids and picking up and sorting test tubes.

The mobile YuMi®could also be used in hospitals for a wide variety of logistics roles. YuMi® may be able to dispense medicines, transport them to where they are needed in hospitals, bring medical supplies to hospital staff and bed linen direct to patients’ bedrooms.

At TMC Innovation Institute, ABB will develop robots that are able to carry out repetitive, delicate and mundane processes, leaving highly skilled medical and laboratory staff free to undertake more valuable roles and ultimately treat more patients. ABB analysis shows that repetitive tasks could be completed up to 50 per cent faster with automation, compared to current manual processes, with the added benefit that robots can work 24 hours a day.

“The healthcare sector is undergoing significant transformation as the diagnosis and treatment of disease advances, while coping with an aging population, increasing costs and a growing worldwide shortage of medical staff. With our new healthcare research and development hub at TMC we are aiming to develop answers to these challenges – together with the best minds in academia, science and medicine,” said Sami Atiya, President of ABB’s Robotics and Discrete Automation business. “Our experience in industrial and collaborative robotics will give us a strong basis to be able to adapt flexible automation to the healthcare sector. Together with our partners at TMC, we will develop cutting-edge robotics solutions. We are working to reduce the number of manual procedures performed by medical staff, improve the accuracy of laboratory work and enhance patient satisfaction and ultimately patient safety.”

Other technologies showcased by ABB at the Healthcare Research Hub include YuMi® robots that could aid in centrifuge tending and test tube handling systems, and an IRB 1200 robot that could execute liquid transfers in a pipetting application. All are common medical laboratory tasks that robotic automation may be able to support by combining consistent performance with a level of flexibility and continuous operation that could increase throughput and quality while minimizing costs.

TMC is the largest medical city in the world with world-class collaborative research resources, including some of the world’s leading companies and hospitals. ABB’s new 5,300 sq ft (500m2 ) Healthcare Hub will be housed at the TMC Innovation Institute, a state-of-the-art hub that fosters collaboration of medicine and cutting-edge technology, connecting start-ups with pioneers in academia and leading technology companies in order to accelerate the development and prototyping of breakthrough medical technology.

“Texas Medical Center, TMC Innovation, and the entire TMC network of member institutions are pleased to welcome ABB on the occasion of its first foray into the healthcare space with this incredible and unprecedented new robotics facility,” emphasized Bill McKeon, President & CEO of Texas Medical Center. He added, “A primary goal across TMC – the largest medical city in the world – is to make research happen faster while simultaneously cutting costs in order to create more rapid and cost-effective solutions for patients who are in desperate need of treatment. ABB’s move into the heart of the Texas Medical Center campus with this first-of-its-kind R&D facility for creating robotics solutions in healthcare will set a new course for advancements in medicine and establish TMC as the nexus for a new kind of synergistic partnership that will shape the future of healthcare for clinicians, researchers, and patients alike.”

Robotic automation in the healthcare sector offers significant opportunity for future growth. According to internal ABB research, the global market is estimated to reach nearly 60,000 non-surgical medical robots by 2025, a fourfold increase from 2018.

Watch the video: https://youtu.be/SA_1vfH5UIk

Media b-roll: https://drive.google.com/file/d/13r9gjaXpLCZmJ69m6m6YyVDM9ONkauQO/view

ABB (ABBN: SIX Swiss Ex) is a technology leader that is driving the digital transformation of industries. With a history of innovation spanning more than 130 years, ABB has four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by the ABB Ability™ digital platform. ABB’s Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com

ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 400,000 robot solutions for a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics

TMC INNOVATION

Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye